业界对Access联盟的看法和经验 新活性物质分工计划 (NASWSI):调查结果和建议
Gaia Geraci1, Robert Smith2, Alison Hansford3
1Clarivate, 70 St. Mary Avenue, London, EC3A 8BE, UK. gaia.geraci@clarivate.com.
对于新活性物质审查的Access Consortium倡议,通常会得到制药公司的积极反. 建议改善可预测性,指导性和流程简化,以加强参与和患者获得药物的机会.
科学领域:
- 监管科学 监管科学
- 制药政策 制药政策
- 药物注册 药物注册 药物注册
背景情况:
- 访问联盟促进了对新活性物质和适应症的联合监管审查.
- 行业参与Access倡议是自愿的,因此利益相关者的看法对其成功至关重要.
研究的目的:
- 收集关于制药公司关联公司关于Access Pathway的认知和经验的见解.
- 确定影响参与的因素以及在Access倡议中需要改进的领域.
主要方法:
- 在Access联盟国家 (澳大利亚,加拿大,新加坡,瑞士,英国) 的制药行业贸易协会开发了一项调查.
- 该调查分发给制药公司的附属公司,以收集他们与Access路径的经验数据.
主要成果:
- 参与Access路径的关联公司报告了大多数积极的经验和对监管机构互动的满意度.
- 不参与的主要原因包括缺乏机会和感知到访问途径的复杂性.
- 在那些参与该倡议的人中观察到继续参与的意愿.
结论:
- 参与的行业关联公司对Access Consortium倡议的看法是积极的.
- 改进建议侧重于提高可预测性,透明度,流程效率,灵活性,协调性以及监管机构与行业的合作.
- 解决感知障碍和增加机会可以促进更大的行业参与,最终加速患者获得创新药物的机会.
更多相关视频
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Regulation
